Genomic and transcriptional aberrations linked to breast cancer pathophysiologies - PubMed (original) (raw)
doi: 10.1016/j.ccr.2006.10.009.
Sandy DeVries, Jane Fridlyand, Paul T Spellman, Ritu Roydasgupta, Wen-Lin Kuo, Anna Lapuk, Richard M Neve, Zuwei Qian, Tom Ryder, Fanqing Chen, Heidi Feiler, Taku Tokuyasu, Chris Kingsley, Shanaz Dairkee, Zhenhang Meng, Karen Chew, Daniel Pinkel, Ajay Jain, Britt Marie Ljung, Laura Esserman, Donna G Albertson, Frederic M Waldman, Joe W Gray
Affiliations
- PMID: 17157792
- DOI: 10.1016/j.ccr.2006.10.009
Free article
Genomic and transcriptional aberrations linked to breast cancer pathophysiologies
Koei Chin et al. Cancer Cell. 2006 Dec.
Free article
Abstract
This study explores the roles of genome copy number abnormalities (CNAs) in breast cancer pathophysiology by identifying associations between recurrent CNAs, gene expression, and clinical outcome in a set of aggressively treated early-stage breast tumors. It shows that the recurrent CNAs differ between tumor subtypes defined by expression pattern and that stratification of patients according to outcome can be improved by measuring both expression and copy number, especially high-level amplification. Sixty-six genes deregulated by the high-level amplifications are potential therapeutic targets. Nine of these (FGFR1, IKBKB, ERBB2, PROCC, ADAM9, FNTA, ACACA, PNMT, and NR1D1) are considered druggable. Low-level CNAs appear to contribute to cancer progression by altering RNA and cellular metabolism.
Comment in
- Integrated breast cancer genomics.
Edgren H, Kallioniemi O. Edgren H, et al. Cancer Cell. 2006 Dec;10(6):453-4. doi: 10.1016/j.ccr.2006.11.007. Cancer Cell. 2006. PMID: 17157784
Similar articles
- High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer.
Staaf J, Jönsson G, Ringnér M, Vallon-Christersson J, Grabau D, Arason A, Gunnarsson H, Agnarsson BA, Malmström PO, Johannsson OT, Loman N, Barkardottir RB, Borg A. Staaf J, et al. Breast Cancer Res. 2010;12(3):R25. doi: 10.1186/bcr2568. Epub 2010 May 6. Breast Cancer Res. 2010. PMID: 20459607 Free PMC article. - Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer.
Bergamaschi A, Kim YH, Wang P, Sørlie T, Hernandez-Boussard T, Lonning PE, Tibshirani R, Børresen-Dale AL, Pollack JR. Bergamaschi A, et al. Genes Chromosomes Cancer. 2006 Nov;45(11):1033-40. doi: 10.1002/gcc.20366. Genes Chromosomes Cancer. 2006. PMID: 16897746 - Novel insights into breast cancer copy number genetic heterogeneity revealed by single-cell genome sequencing.
Baslan T, Kendall J, Volyanskyy K, McNamara K, Cox H, D'Italia S, Ambrosio F, Riggs M, Rodgers L, Leotta A, Song J, Mao Y, Wu J, Shah R, Gularte-Mérida R, Chadalavada K, Nanjangud G, Varadan V, Gordon A, Curtis C, Krasnitz A, Dimitrova N, Harris L, Wigler M, Hicks J. Baslan T, et al. Elife. 2020 May 13;9:e51480. doi: 10.7554/eLife.51480. Elife. 2020. PMID: 32401198 Free PMC article. - DNA amplifications in breast cancer: genotypic-phenotypic correlations.
Shiu KK, Natrajan R, Geyer FC, Ashworth A, Reis-Filho JS. Shiu KK, et al. Future Oncol. 2010 Jun;6(6):967-84. doi: 10.2217/fon.10.56. Future Oncol. 2010. PMID: 20528234 Review. - Copy number alterations: a catastrophic orchestration of the breast cancer genome.
Shahrouzi P, Forouz F, Mathelier A, Kristensen VN, Duijf PHG. Shahrouzi P, et al. Trends Mol Med. 2024 Aug;30(8):750-764. doi: 10.1016/j.molmed.2024.04.017. Epub 2024 May 20. Trends Mol Med. 2024. PMID: 38772764 Review.
Cited by
- Osteopontin is a therapeutic target that drives breast cancer recurrence.
Gu Y, Taifour T, Bui T, Zuo D, Pacis A, Poirier A, Attalla S, Fortier AM, Sanguin-Gendreau V, Pan TC, Papavasiliou V, Lin NU, Hughes ME, Smith K, Park M, Tremblay ML, Chodosh LA, Jeselsohn R, Muller WJ. Gu Y, et al. Nat Commun. 2024 Oct 24;15(1):9174. doi: 10.1038/s41467-024-53023-9. Nat Commun. 2024. PMID: 39448577 Free PMC article. - Inference of chromosome selection parameters and missegregation rate in cancer from DNA-sequencing data.
Xiang Z, Liu Z, Dinh KN. Xiang Z, et al. Sci Rep. 2024 Jul 31;14(1):17699. doi: 10.1038/s41598-024-67842-9. Sci Rep. 2024. PMID: 39085295 Free PMC article. - miR-1204 Positioning in 8q24.21 Involved in the Tumorigenesis of Colorectal Cancer by Targeting MASPIN.
Tian S, Chen M, Jing W, Meng Q, Wu J. Tian S, et al. Protein Pept Lett. 2024;31(7):544-558. doi: 10.2174/0109298665305114240718072029. Protein Pept Lett. 2024. PMID: 39082173 - CD8+ T cell‑related KCTD5 contributes to malignant progression and unfavorable clinical outcome of patients with triple‑negative breast cancer.
Li J, Yao J. Li J, et al. Mol Med Rep. 2024 Sep;30(3):166. doi: 10.3892/mmr.2024.13290. Epub 2024 Jul 19. Mol Med Rep. 2024. PMID: 39027992 Free PMC article. - Cell State Transition Models Stratify Breast Cancer Cell Phenotypes and Reveal New Therapeutic Targets.
Rukhlenko OS, Imoto H, Tambde A, McGillycuddy A, Junk P, Tuliakova A, Kolch W, Kholodenko BN. Rukhlenko OS, et al. Cancers (Basel). 2024 Jun 27;16(13):2354. doi: 10.3390/cancers16132354. Cancers (Basel). 2024. PMID: 39001416 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous